National Guideline Clearinghouse | Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer.

Guideline Title
Cancer Care Ontario Web site [CCO]
Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer.

Bibliographic Source(s)
Clemons M, Amir E, Haynes AE, Eisen A, Trudeau M. Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer. Toronto (ON): Cancer Care Ontario (CCO); 2010 Jan 25. 18 p. (CED-CCO special advice report; no. 16). [8 references]

Guideline Status
This is the current release of the guideline.

The SPECIAL ADVICE report over time will expand to contain new information emerging from their reviewing and updating activities.

Please visit the Cancer Care Ontario Web site [CCO]for details on any new evidence that has emerged and implications to the guidelines.

full-text:
National Guideline Clearinghouse | Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer.